Prognostic values of the presence of disseminated tumor cells in the bone marrow in patients with disseminated stomach cancer before start of treatment with antitumor drugs


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The purpose of our study was to evaluate the frequency and prognostic value of the presence of disseminated tumor cells (DTCs) in the bone marrow (BM) in patients with disseminated gastric cancer (GC). DTCs in BM of 43 patients with disseminated GC were determined by the flow cytometry (DTC-positive cases included those with the presence of at least 1 tumor cell per 10 million myelokaryocytes). The presence of DTCs in BM was detected in 28 of 43 patients (65.1%). In the absence of DTCs in the BM, the progression-free survival and overall survival of patients were significantly higher: 6.07 and 9.5 (log rank p=0.037) versus 11.67 and 22.5 (log rank p=0.029) months, respectively. DTCs in the BM was significantly more often detected in case of localization of primary tumor in the cardioesophageal junction (p=0.05) and in the low-grade and ring-shaped forms of adenocarcinoma (p=0.01 and p=0.024). There were no correlations of DTCs with the sex of patients, localization of distant metastases, the number of metastastatic sites. All patients underwent combined chemotherapy with mFOLFIRINOX. The presence of DTCs in BM is a negative prognostic factor for the progression-free survival and the overall survival of patients with disseminated GC.

Full Text

Restricted Access

About the authors

N. S Besova

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

Email: besovans@mail.iu
PhD, Senior Reseaichei at the Department of Chemotherapy

E. S Obarevich

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

M. M Davydov

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

O. A Beznos

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

N. N Tupitsyn

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

References

  1. Sieqel R., Naishadham D., Jemal A. Cancer statistics. 2012. CA Cancer J. Clin. 2012;62(1):10-29.
  2. Maehara Y., Hasuda S., Abe T., Oki E., Kakeji Y., Ohno S., Sugimachi K. Tumor Angiogenesis and Micrometastasis in Bone Marrow of Patients with Early Gastric Cancer. Clin. Cancer Res. 1998;4:2129-34.
  3. Maehara Y., Yamarnoto M., Oda S., Baba H., Kusumot T., Ohno S., Ichiyoshi Y., Sugimachi K. Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer. Br. J. Cancer. 1996;73:83-7.
  4. Jauch K.W., Heiss M.M., Gruetzner U., Funke I., Pantel K., Babic R., Eissner H.J., Riethmueller G., Schildberg F.W. Prognostic Significance of Bone Marrow Micrometastases in Patients With Gastric Cancer. J. Clin. Oncol. 1996;14(6):1810-17.
  5. Davydov M.I., Tupitsin N.N., Grigorieva T.A., et al. Assessment of minimal bone marrow involvement by flow cytometry in cancer patients. Haematopoiesis Immunol. 2014;12:8-17.
  6. Dasgupta A., Lim A.R., Ghajar C.M. Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol. Oncol. 2017;11:40-61.
  7. Joosse S.A., Gorges T.M., Pantel K. Biology, detection, and clinical implications of circulating tumor cells EMBO. Mol. Med. 2015;7(1):1-11.
  8. Kusumbe A.P. Vascular niches for disseminated tumour cells in bone. J. Bone Oncol. 2016;5:112-16.
  9. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G., Pierga J.Y., Marth C., Oruzio D., Wiedswang G., Solomayer E.F., Kundt G., Strobl B., Fehm T., Wong G.Y., Bliss J., Vincent-Salomon A., Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005;353:793-802.
  10. Kollermann J., Heseding B., Helpap B., Kollermann M.W., Pantel K. Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer. Int. J. Cancer. 1999;84: 145-49.
  11. Pantel K., Izbicki J., Passlick B., Angstwurm M., Haussinger K., Thetter O., Riethmüller G. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996;347:649-53.
  12. Lindemann F., Schlimok G., Dirschedl P., Witte J., Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet. 1992;340:685-89.
  13. Effenberger K.E., Schroeder C., Eulenburg C., Reeh M., Tachezy M., Riethdorf S., Vashist Y.K., Izbicki J.R., Pantel K., Bockhorn M. Disseminated tumor cells in pancreatic cancer-an independent prognosticator of disease progression and survival. Int. J. Cancer. 2012;131:E475-83.
  14. Vashist Y.K., Effenberger K.E., Vettorazzi E., Riethdorf S., Yekebas E.F., Izbicki J.R., Pantel K. Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer. Ann. Surg. 2012;255:1105-12.
  15. Broll R., Lembcke K., Stock C., Zingler M., Duchrow M., Schimmelpenning H., Strik M., Muller G., Kujath P, Bruch H.P Tumor cell dissemination in bone marrow and peritoneal cavity. An immunocytochemical study of patients with stomach or colorectal carcinoma. Langenbecks Arch. Chir. 1996; 381(1):51-8.
  16. Kim H.S., Yi S.Y., Jun H.J., Lee J., Park J.O., Park Y.S., Jang J., Kim H.J., Ko Y., Lim H.Y., Kang W.K. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology. 2007;73:192-97.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies